China ; Dental Implantation ; Humans

Oral Medicine ; education ; trends ; Periodicals as Topic

China ; Congresses as Topic ; Dentistry ; Societies, Dental

Editorial Policies ; Oral Medicine

China ; Congresses as Topic ; Oral Medicine ; Periodicals as Topic

China ; Education, Dental ; Oral Medicine ; education

China ; Humans ; Oral Health ; Oral Hygiene ; Periodontal Diseases ; complications ; Practice Guidelines as Topic

Dental Implantation ; trends ; Humans

The intestinal type of lung adenocarcinoma is a very rare subtype of lung adenocarcinoma, presenting with pulmonary symptoms, but without any gastrointestinal symptoms and pathological changes. The author found 1 case of double primary lung adenocarcinoma of the left lung, which was confirmed by surgery pathology, one for lung adenocarcinoma, one for a rare type of intestinal adenocarcinoma. This paper reviews the relevant literatures of the diagnosis and treatment of this case.

Objective To evaluate the efficacy and safety of XELOX chemotherapy combined with Chinese herbal medicines in patients with obstructive colorectal cancer.MethodsA total of 70 patients with obstructive colorectal cancer were recruited and divided into a XELOX treatment group and a combined treatment group, 35 in each group. The XELOX treatment group received XELOX chemotherapy, while the combined treatment group were received XELOX chemotherapy combined with Chinese herbal medicines. All patients received a 3-week treatment as a cycle, and for 4 cycles. The outcomes were Karnofsky performance status (KPS) and the Zubrod-ECOG-WHO Scale (ZPS). Adverse effects were recorded.ResultsAfter the treatment, the clinical symptoms score (1.62 ± 0.21vs. 2.12 ± 0.31;t=7.900,P<0.01) and ZPS score (1.07 ± 0.33 vs. 2.88 ± 0.41;t=20.346,P<0.01) in the combined treatment group were significantly lower than those in the XELOX treatment group, but the KPS score was significantly higher (93.42 ± 5.56vs. 86.43 ± 5.93;t=5.087, P<0.01). The follow-up showed that the 3-year survival rates in the combined treatment group was significantly lower than those in the XELOX treatment group (80.00%vs. 57.14%;χ2=4.242,P=0.039). The incidence of leukopenia (11.43%vs. 34.29%;χ2=3.970,P<0.05), anemia (5.71%vs. 22.86%;χ2=4.200,P<0.05), nausea/vomiting (8.57%vs. 28.57%;χ2=4.629,P<0.05), and diarrhea (2.86%vs. 20.00%;χ2=5.081,P<0.05) in the combined treatment group were significantly lower than those in the XELOX treatment group. Conclusion XELOX chemotherapy combined with Chinese herbal medicines can improve clinical symptoms, performance status, and alleviate adverse effects in patients with obstructive colorectal cancer.